Oral Rivaroxaban for Symptomatic Venous Thromboembolism
Open accessThe DOI matches its Crossref record, with a small difference in title or year; 20 of the 20 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Rivaroxaban, an oral factor Xa inhibitor, may provide a simple, fixed-dose regimen for treating acute deep-vein thrombosis (DVT) and for continued treatment, without the need for laboratory monitoring. METHODS: We conducted an open-label, randomized, event-driven, noninferiority study that compared oral rivaroxaban alone (15 mg twice daily for 3 weeks, followed by 20 mg once daily) with subcutaneous enoxaparin followed by a vitamin K antagonist (either warfarin or acenocoumarol) for 3, 6, or 12 months in patients with acute, symptomatic DVT. In parallel, we carried out a double-blind, randomized, event-driven superiority study that compared rivaroxaban alone (20 mg once daily) with placebo for an additional 6 or 12 months in patients who had completed 6 to 12 months of treatment for venous thromboembolism. The primary efficacy outcome for both studies was recurrent venous thromboembolism. The principal safety outcome was major bleeding or clinically relevant nonmajor bleeding in the initial-treatment study and major bleeding in the continued-treatment study. RESULTS: The study of rivaroxaban for acute DVT included 3449 patients: 1731 given rivaroxaban and 1718 given enoxaparin plus a vitamin K antagonist. Rivaroxaban had noninferior efficacy with respect to the primary outcome (36 events [2.1%], vs. 51 events with enoxaparin-vitamin K antagonist [3.0%]; hazard ratio, 0.68; 95% confidence interval [CI], 0.44 to 1.04; P<0.001). The principal safety outcome occurred in 8.1% of the patients in each group. In the continued-treatment study, which included 602 patients in the rivaroxaban group and 594 in the placebo group, rivaroxaban had superior efficacy (8 events [1.3%], vs. 42 with placebo [7.1%]; hazard ratio, 0.18; 95% CI, 0.09 to 0.39; P<0.001). Four patients in the rivaroxaban group had nonfatal major bleeding (0.7%), versus none in the placebo group (P=0.11). CONCLUSIONS: Rivaroxaban offers a simple, single-drug approach to the short-term and continued treatment of venous thrombosis that may improve the benefit-to-risk profile of anticoagulation. (Funded by Bayer Schering Pharma and Ortho-McNeil; ClinicalTrials.gov numbers, NCT00440193 and NCT00439725.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“We conducted a subgroup analysis of the evidence of DOACs vs VKAs 86-97 and found no interaction between the specific agent used and the risk of mortality, PE, symptomatic DVT, or major bleeding.”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [88]
In the citing paper
“We conducted a subgroup analysis of the evidence of DOACs vs VKAs 86-97 and found no interaction between the specific agent used and the risk of mortality, PE, symptomatic DVT, or major bleeding.”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [88]
In the citing paper
“We conducted a subgroup analysis of the evidence of DOACs vs VKAs 86-97 and found no interaction between the specific agent used and the risk of mortality, PE, symptomatic DVT, or major bleeding.”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [88]
In the citing paper
“We conducted a subgroup analysis of the evidence of DOACs vs VKAs 86-97 and found no interaction between the specific agent used and the risk of mortality, PE, symptomatic DVT, or major bleeding.”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [88]
Citations
Cites
Dabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism
Schulman, S., Kearon, C., Kakkar, A. K., Mismetti, P., Schellong, S., Eriksson, H., Baanstra, D., Schnee, J., & Goldhaber, S. Z. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0906598 · Cited by 2,583
The Long-Term Clinical Course of Acute Deep Venous Thrombosis
Prandoni, P., Lensing, A. W. A., Cogo, A., Cuppini, S., Villalta, S., Carta, M., Cattelan, A. M., Polistena, P., Bernardi, E., & Prins, M. H. (1996) · Annals of Internal Medicine · doi:10.7326/0003-4819-125-1-199607010-00001 · Cited by 2,109
Antithrombotic Therapy for Venous Thromboembolic Disease
Kearon, C., Kahn, S. R., Agnelli, G., Goldhaber, S., Raskob, G. E., & Comerota, A. J. (2008) · Chest · doi:10.1378/chest.08-0658 · Cited by 1,996
Statistics in Medicine — Reporting of Subgroup Analyses in Clinical Trials
Wang, R., Lagakos, S. W., Ware, J. H., Hunter, D. J., & Drazen, J. M. (2007) · New England Journal of Medicine · doi:10.1056/nejmsr077003 · Cited by 1,445
Turpie, A. G., Lassen, M. R., Davidson, B. L., Bauer, K. A., Gent, M., Kwong, L. M., Cushner, F. D., Lotke, P. A., Berkowitz, S. D., Bandel, T. J., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60734-0 · Cited by 981
In-Stent Restenosis in the Drug-Eluting Stent Era
Dangas, G. D., Claessen, B. E., Caixeta, A., Sanidas, E. A., Mintz, G. S., & Mehran, R. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.07.028 · Cited by 803
Incidence of Venous Thromboembolism: A Community-based Study in Western France
Oger, E., & the EPI-GETBO Study Group (2000) · Thrombosis and Haemostasis · doi:10.1055/s-0037-1613887 · Cited by 711
KUBITZA, D., BECKA, M., VOITH, B., ZUEHLSDORF, M., & WENSING, G. (2005) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2005.06.011 · Cited by 649
Rodger, M. A., Kahn, S. R., Wells, P. S., Anderson, D. A., Chagnon, I., Le Gal, G., Solymoss, S., Crowther, M., Perrier, A., White, R., et al. (2008) · Canadian Medical Association Journal · doi:10.1503/cmaj.080493 · Cited by 581
Research works printed but not linked: 1
- Hutten BA, 2006, Cochrane Database Syst Rev, 1, CD001367
Cited by
Items 801–900 of 1,010
Sulaiman, K. A. A., Hafiz, A. M., Badreldin, H. A., Korayem, G. B., Alsuwayyid, F., Alrashidi, A., Alhijris, M., Almutairi, F. F., Alharthi, F., Alghamdi, S. A., et al. (2022) · Journal of Investigative Medicine High Impact Case Reports · doi:10.1177/23247096221099893 · Cited by 26
Bleeding events with dabigatran or warfarin in patients with venous thromboembolism
Goldhaber, S. Z., Kakkar, A. K., Kearon, C., Eriksson, H., Kreuzer, J., Feuring, M., Hantel, S., Friedman, J. E., Schellong, S., Schulman, S., et al. (2015) · Thrombosis and Haemostasis · doi:10.1160/th15-04-0319 · Cited by 26
Management of Non-Vitamin K Antagonist Oral Anticoagulants in the Perioperative Setting
Dincq, A.-S., Lessire, S., Douxfils, J., Dogné, J., Gourdin, M. J., & Mullier, F. (2014) · BioMed Research International · doi:10.1155/2014/385014 · Cited by 27
Ageno, W., Mantovani, L. G., Haas, S. K., Kreutz, R. H., Monje, D., Schneider, J., van Eickels, M., Gebel, M., & Turpie, A. G. G. (2017) · TH Open · doi:10.1055/s-0037-1603924 · Cited by 26
Bleeding in patients receiving non-vitamin K oral anticoagulants: clinical trial evidence
Bracey, A., Shatila, W., & Wilson, J. M. (2018) · Therapeutic Advances in Cardiovascular Disease · doi:10.1177/1753944718801554 · Cited by 31
Evaluation of oral factor Xa inhibitor‐associated extracranial bleeding reversal with andexanet alfa
Nederpelt, C. J., Naar, L., Sylvester, K. W., Barra, M. E., Roberts, R. J., Velmahos, G. C., Kaafarani, H. M. A., Rosenthal, M. G., & King, D. R. (2020) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.15031 · Cited by 26
Ethnoracial variations in venous thrombosis: Implications for management, and a call to action
Xu, Y., Siegal, D. M., & Anand, S. S. (2020) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.15140 · Cited by 28
Perino, A. C., Fan, J., Schmitt, S. K., Guo, J. D., Hlavacek, P., Din, N., Kothari, M., Pundi, K. N., Russ, C., Emir, B., et al. (2021) · Circulation Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.121.008005 · Cited by 26
“For patients with weight ratios greater or less than the stated threshold, we (1) excluded the outlier measurement if ≥4 total weight measurements were available in the 90 days prior through 90 days after index VTE by identifying the extreme weight measurement; (2) excluded the patient if ≤3 total weight measurements…”
InfluentialDirect oral anticoagulants for use in paediatrics
Jaffray, J., & Young, G. (2022) · The Lancet Child & Adolescent Health · doi:10.1016/s2352-4642(21)00343-6 · Cited by 29
Thompson, L. E., Davis, B. H., Narayan, R., Goff, B., Brown, T. M., & Limdi, N. A. (2022) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2714 · Cited by 28
Shu, L., Bakradze, E., Omran, S. S., Giles, J. A., Amar, J. Y., Henninger, N., Elnazeir, M., Liberman, A. L., Moncrieffe, K., Rotblat, J., et al. (2022) · Neurology · doi:10.1212/wnl.0000000000201122 · Cited by 30
Cancer‐associated thrombosis and drug–drug interactions of antithrombotic and antineoplastic agents
Bölek, H., & Ürün, Y. (2023) · Cancer · doi:10.1002/cncr.34937 · Cited by 30
Backus, B. E., Beyer‐Westendorf, J., Body, R. M., Lindner, T., Möckel, M., Sehgal, V., Parry‐Jones, A., Seiffge, D. J., & Gibler, B. (2023) · European Journal of Emergency Medicine · doi:10.1097/mej.0000000000001049 · Cited by 33
Cao, W., Xie, S., Liu, Y., Ran, P., Zhang, Z., Fang, Q., & Li, X. (2023) · Advanced Functional Materials · doi:10.1002/adfm.202312866 · Cited by 26
Sarich, T. C., Peters, G. R., Berkowitz, S. D., Misselwitz, F., Nessel, C. C., Burton, P. B. J., Cook‐Bruns, N., Lensing, A. W. A., Haskell, L. P., Perzborn, E., et al. (2013) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12136 · Cited by 27
Radcliff, K. E., Ong, A., Parvizi, J., Post, Z. D., & Orozco, F. (2014) · Orthopaedic Surgery · doi:10.1111/os.12085 · Cited by 26
How I manage venous thromboembolism risk in hospitalized medical patients
Dobromirski, M., & Cohen, A. T. (2012) · Blood · doi:10.1182/blood-2012-03-378901 · Cited by 34
Gómez‐Outes, A., Suárez-Gea, Lecumberri, R., Terleira‐Fernández, A. I., Vargas, E., & Rocha (2013) · Vascular Health and Risk Management · doi:10.2147/vhrm.s35843 · Cited by 28
Piazza, G. (2015) · Vascular Medicine · doi:10.1177/1358863x14568706 · Cited by 30
The new oral anticoagulants in atrial fibrillation: Once daily or twice daily?
Renda, G., & Caterina, R. D. (2013) · Vascular Pharmacology · doi:10.1016/j.vph.2013.07.003 · Cited by 28
“The results of such a regimen were of non-inferiority compared with low molecular weight heparin (LMWH)/VKA for efficacy, with similar findings for the principal safety outcome of first major or clinically relevant non-major bleeding [37,38].”
ResultMassive human rivaroxaban overdose
Lehmann, T., Hofer, K. E., Baumann, M., Hasler, K., Ceschi, A., Kupferschmidt, H., Rohde, G., & Korte, W. C. (2014) · Thrombosis and Haemostasis · doi:10.1160/th14-02-0138 · Cited by 27
Oswald, E., Velik‐Salchner, C., Innerhofer, P., Tauber, H., Auckenthaler, T., Ulmer, H., & Streif, W. (2014) · Blood Coagulation & Fibrinolysis · doi:10.1097/mbc.0000000000000203 · Cited by 26
Prandoni, P., Barbar, S., Milan, M., Vedovetto, V., & Pesavento, R. (2013) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2013.09.005 · Cited by 26
“The EINSTEIN DVT and PE studies randomized 3449 patients with isolated DVT and 4832 patients with primary PE, respectively, to receive rivaroxaban (15 mg bid for 3 weeks followed by 20 mg once daily) or enoxaparin plus a vitamin K antagonist for 3, 6 or 12 months [75,76].”
MethodLlau, J. V., Ferrandis, R., Castillo, J., de Andrés, J., Gomar, C. G., Gómez‐Luque, A., Hidalgo, F., & Torres, L. M. (2012) · Revista Española de Anestesiología y Reanimación · doi:10.1016/j.redar.2012.01.007 · Cited by 32
Diagnose und Management der akuten pulmonalen Embolie: ESC-Leitlinien 2014
Saar, J. A., & Maack, C. (2015) · Herz · doi:10.1007/s00059-015-4378-0 · Cited by 30
Werth, S., Bauersachs, R. M., Gerlach, H. E., Rabe, E., Schellong, S., & Beyer‐Westendorf, J. (2016) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-016-1354-3 · Cited by 26
Zhang, Z., Zhai, Z., Yang, Y., Wan, J., Xie, W., Zhu, J., Shen, Y. H., & Wang, C. (2017) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-017-1473-5 · Cited by 26
“7% within 6–12 months) [13, 18, 19], yet similar with the other registry and observed studies (2.”
ResultNicklaus, M. D., Ludwig, S., & Kettle, J. K. (2017) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155217690922 · Cited by 27
“The EINSTEIN trials demonstrated noninferiority of rivaroxaban compared to a vitamin-K-antagonist (VKA) in the general population.(4,5) The EINSTEIN deep venous thrombosis (DVT) and pulmonary embolus (PE) trials featured just 6% and 4.”
MethodWhat have we learned from real-world NOAC studies in venous thromboembolism treatment?
Beyer‐Westendorf, J. (2018) · Thrombosis Research · doi:10.1016/j.thromres.2018.01.034 · Cited by 28
Keller, L., Marten, S., Hecker, J. S., Şahin, K., Tittl, L., & Beyer‐Westendorf, J. (2018) · International Journal of Cardiology · doi:10.1016/j.ijcard.2017.10.097 · Cited by 28
Yamashita, Y., Morimoto, T., Toyota, T., Shiomi, H., Makiyama, T., Ono, K., & Kimura, T. (2018) · Thrombosis Research · doi:10.1016/j.thromres.2018.04.008 · Cited by 30
Bertoletti, L., Benhamou, Y., Béjot, Y., Maréchaux, S., Cheggour, S., Aleil, B., Lellouche, N., Dillinger, J., & Delluc, A. (2018) · Blood Reviews · doi:10.1016/j.blre.2018.01.002 · Cited by 30
DIRECT ORAL ANTICOAGULANTS IN PATIENTS AFFECTED BY MAJOR CONGENITAL THROMBOPHILIA
Serrao, A., Lucani, B., Mansour, D., Ferretti, A., Baldacci, E., Santoro, C., Foà, R., & Chistolini, A. (2019) · Mediterranean Journal of Hematology and Infectious Diseases · doi:10.4084/mjhid.2019.044 · Cited by 27
Optimal management of hormonal contraceptives after an episode of venous thromboembolism
Klok, F. A., & Barco, S. (2019) · Thrombosis Research · doi:10.1016/s0049-3848(19)30357-3 · Cited by 27
Cáliz, R., Fontecha, P. D. D. C., Galindo-Izquierdo, M., Longo, F. J. L., Zamora, M. Á. M., Santamaría, A., Pliego, O. A., Lozano, M. J. C., Beltrán, M. P. D., Carmona, L., et al. (2019) · Reumatología Clínica · doi:10.1016/j.reuma.2018.11.003 · Cited by 34
Use of direct‐acting oral anticoagulants in solid organ transplantation: A systematic review
Bixby, A. L., Lichvar, A. B., Salerno, D. M., & Park, J. M. (2020) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2485 · Cited by 26
Karathanos, C., Nana, P., Spanos, K. T., Kouvelos, G. N., Brotis, A. G., Matsagas, M. I., & Giannoukas, A. D. (2021) · Journal of Vascular Surgery Venous and Lymphatic Disorders · doi:10.1016/j.jvsv.2021.04.016 · Cited by 27
Cook, R. M., Rondina, M. T., & Horton, D. (2014) · Annals of Pharmacotherapy · doi:10.1177/1060028014533304 · Cited by 26
“3%) in EINSTEIN had a known thrombophilic condition, although details on the types of thrombophilia have not been published.(26) Taken together, the results of EINSTEIN suggest that rivaroxaban is at least as effective as traditional therapy with LMWH-VKA and, in some settings, may provide overall clinical benefit.”
MethodResultMearns, E. S., Coleman, C. I., Patel, D. R., Saulsberry, W. J., Corman, A. R., Li, D., Hernández, A. V., & Kohn, C. G. (2015) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.12914 · Cited by 28
Weitz, J. I., & Jaffer, I. (2016) · Polskie Archiwum Medycyny Wewnętrznej · doi:10.20452/pamw.3547 · Cited by 28
Recent developments in the diagnosis and treatment of pulmonary embolism
van der Hulle, T., Dronkers, C. E. A., Klok, F. A., & Huisman, M. V. (2015) · Journal of Internal Medicine · doi:10.1111/joim.12404 · Cited by 28
Miller, M. P., Trujillo, T. C., & Nordenholz, K. E. (2013) · The American Journal of Emergency Medicine · doi:10.1016/j.ajem.2013.11.044 · Cited by 25
“Rivaroxaban is also FDA approved for the prevention of venous thromboembolism (VTE) after orthopedic surgery and very recently was approved for treatment of VTE [7].”
BackgroundRisk stratification and treatment strategy of pulmonary embolism
Penaloza, A., Roy, P., & Kline, J. A. (2012) · Current Opinion in Critical Care · doi:10.1097/mcc.0b013e32835444bc · Cited by 26
Zaarour, M., Hassan, S., Thumallapally, N., & Dai, Q. (2015) · Case Reports in Hematology · doi:10.1155/2015/275380 · Cited by 25
“VTE [8] HR = 0.”
BackgroundNew Trends in Anticoagulation Therapy
SMITH, M. H. D., Wakam, G. K., Wakefield, T. W., & Obi, A. T. (2018) · Surgical Clinics of North America · doi:10.1016/j.suc.2017.11.003 · Cited by 26
Coulis, A. A., & Mackey, W. C. (2018) · Clinical Therapeutics · doi:10.1016/j.clinthera.2018.10.009 · Cited by 27
Covert, K. L., & Branam, D. L. (2020) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/zxaa059 · Cited by 26
“Based on the results of the EINSTEIN and EINSTEIN-PE trials, rivaroxaban was approved by FDA for the treatment of acute DVT and PE in 2012.(3,5) The first phase of the EINSTEIN trial compared rivaroxaban to war-”
BackgroundMethodTreatment of Venous Thromboembolism in Special Populations with Direct Oral Anticoagulants
Bavalia, R., Middeldorp, S., Weißer, G., & Espinola–Klein, C. (2020) · Thrombosis and Haemostasis · doi:10.1055/s-0040-1710314 · Cited by 26
Literature review of distal deep vein thrombosis
Skeik, N., Smith, J. E., Jensen, J. D., Nowariak, M. E., Manunga, J. M., & Mirza, A. K. (2021) · Journal of Vascular Surgery Venous and Lymphatic Disorders · doi:10.1016/j.jvsv.2021.01.018 · Cited by 28
Shaikh, F., Wynne, R. M., Castelino, R. L., Inglis, S. C., & Ferguson, C. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.732828 · Cited by 26
Anticoagulation Treatment in Venous Thromboembolism: Options and Optimal Duration
Diavati, S., Sagris, Μ., Terentes-Printzios, D. G., & Vlachopoulos, C. V. (2021) · Current Pharmaceutical Design · doi:10.2174/1381612827666211111150705 · Cited by 32
Williams, B., Saseen, J. J., Trujillo, T. C., & Palkimas, S. (2021) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-021-02587-0 · Cited by 28
Long-Term Management of Pulmonary Embolism: A Review of Consequences, Treatment, and Rehabilitation
Højen, A. A., Nielsen, P. B., Overvad, T. F., Albertsen, I. E., Klok, F. A., Rolving, N., Søgaard, M., & Ording, A. G. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11195970 · Cited by 32
Amin, A., & Marrs, J. C. (2015) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/1076029615601492 · Cited by 28
Castellucci, L. A., Gal, G. L., Rodger, M. A., & Carrier, M. (2014) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.12501 · Cited by 27
Novel anticoagulants and antiplatelet agents; a guide for the urologist
Ellis, G., Camm, A. J., & Datta, S. N. (2015) · British Journal of Urology · doi:10.1111/bju.13131 · Cited by 26
Barra, S., Paiva, L., Providencia, R. A., Fernandes, A. S., Nascimento, J. H. M., & Marques, A. L. (2012) · Thrombosis Research · doi:10.1016/j.thromres.2012.03.010 · Cited by 26
“The new oral anticoagulants Dabigatran [6] and Rivaroxaban [7] have emerged as new ambulatory therapeutics for patients with venous thromboembolism.”
BackgroundWypasek, E., Potaczek, D. P., Alhenc‐Gelas, M., & Undas, A. (2014) · Thrombosis Research · doi:10.1016/j.thromres.2014.01.023 · Cited by 26
The new oral anti-coagulants and the phase 3 clinical trials - a systematic review of the literature
Tahir, F., Riaz, H., Riaz, T., Badshah, M. B., Riaz, I. B., Hamza, A., & Mohiuddin, H. (2013) · Thrombosis Journal · doi:10.1186/1477-9560-11-18 · Cited by 30
Risk assessment for recurrence and optimal agents for extended treatment of venous thromboembolism
Agnelli, G., & Becattini, C. (2013) · Hematology · doi:10.1182/asheducation-2013.1.471 · Cited by 27
DVT Management and Outcome Trends, 2001 to 2014
Morillo, R., Jiménez, D., Arregui, M. Á. A., Mastroiacovo, D., Wells, P. S., Samperiz, A. L., de Sousa, M. S., Muriel, A., Yusen, R. D., Monréal, M., et al. (2016) · CHEST Journal · doi:10.1016/j.chest.2016.03.046 · Cited by 26
Direct-Acting Oral Anticoagulants: Practical Considerations for Emergency Medicine Physicians
Peacock, W. F., Rafique, Z., & Singer, A. J. (2016) · Emergency Medicine International · doi:10.1155/2016/1781684 · Cited by 28
Anticoagulant Preferences and Concerns among Venous Thromboembolism Patients
Lutsey, P. L., Horvath, K. J., Fullam, L., Moll, S., Rooney, M. R., Cushman, M., & Zakai, N. A. (2018) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1625985 · Cited by 28
Clinically relevant non-major bleeding with oral anticoagulants: non-major may not be trivial.
Franco, L., Becattini, C., Vanni, S., Sbrojavacca, R., Nitti, C., Manina, G., Masotti, L., Pomero, F., Cattinelli, S., Cappelli, R., et al. (2018) · Blood transfusion · doi:10.2450/2017.0335-16 · Cited by 26
Bang, C. S., Joo, M. K., Kim, B., Kim, J. S., Park, C. H., Ahn, J. Y., Lee, B. E., Lee, B. E., Yang, H., Cho, Y. K., et al. (2019) · Gut and Liver · doi:10.5009/gnl19009 · Cited by 25
Systemic Lupus Erythematosus and Antiphospholipid Antibody Syndrome
Kokosi, M. A., Lams, B., & Agarwal, S. (2019) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2019.06.001 · Cited by 27
Recio‐Boiles, A., Veeravelli, S., Vondrak, J., Babiker, H. M., Scott, A. J., Shroff, R. T., Patel, H., Elquza, E., & McBride, A. (2019) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v11.i10.866 · Cited by 25
Who should get long-term anticoagulant therapy for venous thromboembolism and with what?
Rodger, M. A., & Gal, G. L. (2018) · Blood Advances · doi:10.1182/bloodadvances.2018020230 · Cited by 28
Randrianarisoa, E., Kopp, H., Balletshofer, B. M., Jaschonek, K. G., Kanz, L., Haering, H.-U., & Rittig, K. (2013) · Blood Coagulation & Fibrinolysis · doi:10.1097/mbc.0b013e3283626238 · Cited by 25
Current Antithrombotic Treatments for Cardiovascular Diseases: A Comprehensive Review
Galanti, K., Marino, M. D., Mansour, D., Testa, S., Rossi, D., Scollo, C., Magnano, R., Pezzi, L., D’Alleva, A., Forlani, D., et al. (2024) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2508281 · Cited by 27
Will NOACs become the new standard of care in anticoagulation therapy?
Oktay, E. (2015) · International Journal of the Cardiovascular Academy · doi:10.1016/j.ijcac.2015.06.007 · Cited by 24
Treatment options for venous thromboembolism: lessons learnt from clinical trials
McRae, S. J. (2014) · Thrombosis Journal · doi:10.1186/s12959-014-0027-8 · Cited by 26
Willett, K. C., & Morrill, A. M. (2017) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s88911 · Cited by 24
Pulmonary embolism response teams
Serhal, M., Haddadin, I., Heresi, G. A., Hornacek, D., Shishehbor, M. H., & Bartholomew, J. R. (2017) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-017-1498-9 · Cited by 28
Direct Oral Anticoagulants in Cancer Patients. Time for a Change in Paradigm
Wojtukiewicz, M. Z., Skalij, P., Tokajuk, P., Polityńska, B., Wojtukiewicz, A. M., Tucker, S. C., & Honn, K. V. (2020) · Cancers · doi:10.3390/cancers12051144 · Cited by 24
Rivaroxaban as an Alternative Agent for Heparin‐Induced Thrombocytopenia
Farasatinasab, M., Zarei, B., Moghtadaei, M., Nasiripour, S., Ansarinejad, N., & Zarei, M. (2020) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.1635 · Cited by 24
“The Journal of Clinical Pharmacology 2020, 60(10) 1362–1366 © 2020, The American College of Clinical Pharmacology DOI: 10.”
BackgroundWysokiński, W. E., Froehling, D. A., Houghton, D. E., McBane, R. D., Vlazny, D. T., Bott‐Kitslaar, D. M., Kuczmik, W., Sutkowska, K., Bator, K., Hodge, D. O., et al. (2020) · European Journal Of Haematology · doi:10.1111/ejh.13471 · Cited by 25
Clinical Guidelines for Drug-induced Peptic Ulcer, 2020 Revised Edition
Joo, M. K., Park, C. H., Kim, J. S., Park, J. M., Ahn, J. Y., Lee, B. E., Lee, J. H., Yang, H., Cho, Y. K., Bang, C. S., et al. (2020) · Korean Journal of Gastroenterology · doi:10.4166/kjg.2020.76.3.108 · Cited by 24
Balancing ischaemia and bleeding risks with novel oral anticoagulants
Baber, U., Mastoris, I., & Mehran, R. (2014) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2014.170 · Cited by 29
Gutiérrez‐Chico, J. L., & Mehilli, J. (2013) · Drugs · doi:10.1007/s40265-013-0135-y · Cited by 24
Clinical Review of Pulmonary Embolism: Diagnosis, Prognosis, and Treatment
Hunt, J. M., & Bull, T. (2011) · Medical Clinics of North America · doi:10.1016/j.mcna.2011.08.003 · Cited by 26
“Included in this report, the investigators published a long-term continuation study examining patients with VTE who had previously completed 6 to 12 months of treatment with oral VKA and were then randomized to either placebo or rivaroxaban for an additional 6 to 12 months.(59) There was a small increased risk of sign…”
BackgroundEmerging options in the treatment of deep vein thrombosis and pulmonary embolism
Brenner, B., & Hoffman, R. (2011) · Blood Reviews · doi:10.1016/j.blre.2011.04.003 · Cited by 27
The promise of novel direct oral anticoagulants
Hoffman, R., & Brenner, B. (2012) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2012.06.004 · Cited by 27
Prins, M. H., & Lensing, A. W. A. (2013) · Thrombosis Journal · doi:10.1186/1477-9560-11-13 · Cited by 25
The newer direct oral anticoagulants: a practical guide
Thachil, J. V. (2014) · Clinical Medicine · doi:10.7861/clinmedicine.14-2-165 · Cited by 25
Developments in the management and treatment of pulmonary embolism
Limbrey, R., & Howard, L. (2015) · European Respiratory Review · doi:10.1183/16000617.00006614 · Cited by 28
Deep Venous Thrombosis of the Upper and Lower Extremity
Hattab, Y., Kung, S., Fasanya, A., Ma, K., Singh, A. C., & DUMONT, T. L. (2017) · Critical Care Nursing Quarterly · doi:10.1097/cnq.0000000000000165 · Cited by 28
Incorporating Comprehensive Management of Direct Oral Anticoagulants into Anticoagulation Clinics
Mohammad, I., Korkis, B., & Garwood, C. L. (2017) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1991 · Cited by 29
Robertson, L., Yeoh, S. E., & Ramli, A. H. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011088.pub2 · Cited by 29
Søgaard, M., Nielsen, P. B., Skjøth, F., Kjældgaard, J. N., Coleman, C. I., & Larsen, T. B. (2018) · The American Journal of Medicine · doi:10.1016/j.amjmed.2018.01.041 · Cited by 27
on behalf of the COSIMO Investigators, Cohen, A. T., Maraveyas, A., Beyer‐Westendorf, J., Lee, A. Y. Y., Mantovani, L. G., & Bach, M. (2018) · Thrombosis Journal · doi:10.1186/s12959-018-0176-2 · Cited by 24
López-Núñez, J. J., Pérez-Andrés, R., Micco, P. D., Schellong, S., Cuervo, C. G., Sahuquillo, J., Ciammaichella, M. M., Morales, M., Bosevski, M., Monréal, M., et al. (2019) · TH Open · doi:10.1055/s-0039-1683970 · Cited by 25
Racial and Ethnic Differences in Response to Anticoagulation: A Review of the Literature
Gibson, C. M., & Yuet, W. C. (2019) · Journal of Pharmacy Practice · doi:10.1177/0897190019894142 · Cited by 25
How I treat obese patients with oral anticoagulants
Wang, T., & Carrier, M. (2020) · Blood · doi:10.1182/blood.2019003528 · Cited by 29
Cerdà, P., Becattini, C., Iriarte, A., Cortés-Hernández, J., Corbella, X., & Riera‐Mestre, A. (2020) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2020.05.012 · Cited by 25
Safety and Efficacy of Direct Oral Anticoagulants in Patients With Moderate to Severe Cirrhosis
Oldham, M., Palkimas, S., & Hedrick, A. (2021) · Annals of Pharmacotherapy · doi:10.1177/10600280211047433 · Cited by 25
A review of the fixed dose use of new oral anticoagulants in obese patients: Is it really enough?
Güler, E., Güler, G. B., Demır, G. G., & Hatipoğlu, S. (2015) · The Anatolian Journal of Cardiology · doi:10.5152/anatoljcardiol.2015.6532 · Cited by 26
Erratum: Balancing ischaemia and bleeding risks with novel oral anticoagulants
Baber, U., Mastoris, I., & Mehran, R. (2014) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2014.204 · Cited by 24
Lanitis, T., Leipold, R., Hamilton, M., Rublee, D., Quon, P., Browne, C., & Cohen, A. T. (2016) · Clinical Therapeutics · doi:10.1016/j.clinthera.2016.01.020 · Cited by 23
“Estimates suggest a cumulative risk of approximately 25% to 40% over a 10-year period,(3,4) with the risk being highest in the first 6 to 12 months after the initial event and a residual risk remaining over patients’ lifetimes.(3,5) Reductions in the risk of recurrence, including the use of effective and safe anticoag…”
BackgroundBarra, S., Paiva, L., Providencia, R. A., Fernandes, A. S., & Marques, A. L. (2013) · Clinical Cardiology · doi:10.1002/clc.22144 · Cited by 23
Metadata
- Authors
- The EINSTEIN Investigators
- Corresponding author
- The EINSTEIN Investigators
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2010-12-23
- Volume
- 363
- Issue
- 26
- Pages
- 2499-2510
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2115787552
- Cited by
- 3,237
- References
- 19
- Citations by year
- 2026: 90 · 2025: 105 · 2024: 118 · 2023: 153 · 2022: 169 · 2021: 189 · 2020: 261 · 2019: 242 · 2018: 248 · 2017: 232 · 2016: 300 · 2015: 267 · 2014: 290 · 2013: 255 · 2012: 188
- FWCI
- 148.86
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Research Publications (Maastricht University) (publishedVersion, other-oa)
- Pure Amsterdam UMC (publishedVersion)
- ORBi (University of Liège) (acceptedVersion, other-oa)
- Murdoch University Research Portal (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- HAL (submittedVersion)
- Universitätsbibliographie, Universität Duisburg-Essen (submittedVersion)
- DIAL (Catholic University of Leuven) (submittedVersion)
- Flinders Academic Commons (Flinders University) (submittedVersion)
- UCL Discovery (University College London) (submittedVersion)
- IrInSubria (University of Insubria) (submittedVersion)
- IRIS (submittedVersion)
- SERVAL (Université de Lausanne) (submittedVersion)
- Archive ouverte UNIGE (University of Geneva) (submittedVersion)
- Archive ouverte UNIGE (University of Geneva) (submittedVersion, cc-by)
- Research Publications (Maastricht University) (submittedVersion)
- Topics
- Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
- Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
- Keywords
- rivaroxaban, oral factor Xa inhibitors, venous thromboembolism, deep vein thrombosis, continuation treatment, recurrent venous thromboembolism, enoxaparin, vitamin K antagonists, warfarin, acenocoumarol, major bleeding, non-inferiority
- MeSH terms
- Rivaroxaban, Acenocoumarol, Acute Disease, Administration, Oral, Aged, Anticoagulants, Double-Blind Method, Female, Hemorrhage, Humans, Injections, Subcutaneous, Male, Middle Aged, Morpholines, Pulmonary Embolism, Thiophenes, Vitamin K, Warfarin, Enoxaparin, Venous Thrombosis, Kaplan-Meier Estimate, Venous Thromboembolism, Intention to Treat Analysis, Factor Xa Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.